Compare URBN & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URBN | CRSP |
|---|---|---|
| Founded | 1970 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 4.9B |
| IPO Year | 1995 | 2016 |
| Metric | URBN | CRSP |
|---|---|---|
| Price | $76.30 | $50.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | ★ $86.91 | $70.29 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 05-20-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.78 | N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $6,165,376,000.00 | $289,590,000.00 |
| Revenue This Year | $10.67 | $807.72 |
| Revenue Next Year | $7.01 | $172.52 |
| P/E Ratio | $55.92 | ★ N/A |
| Revenue Growth | 11.07 | ★ 9169.85 |
| 52 Week Low | $59.54 | $40.00 |
| 52 Week High | $84.35 | $78.48 |
| Indicator | URBN | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 46.52 |
| Support Level | $73.70 | $46.15 |
| Resistance Level | $78.35 | $59.61 |
| Average True Range (ATR) | 2.52 | 2.88 |
| MACD | 0.11 | -0.28 |
| Stochastic Oscillator | 82.46 | 16.02 |
Founded in 1970, Philadelphia-based Urban Outfitters is a multibrand apparel and home goods retailer that operates nearly 800 stores and e-commerce in the US, which accounts for about 87% of sales, as well as in other regions. Its retail nameplates are Urban Outfitters (22% of fiscal 2026 sales), Free People/Movement (26%), and Anthropologie (42%). Retail accounted for 86% of fiscal 2026 revenue, but Urban Outfitters also sells products through a wholesale operation, owns some restaurants, and operates a fast-growing clothing rental and resale business called Nuuly (9% of sales). Urban Outfitters primarily markets to young adults and offers products across apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.